Deferasirox
Product Name: Deferasirox
CAS No.: 201530-41-8
Molecular Formula: C21H15N3O4
Molecular Weight: 373.368
Purity: 99%
Vapor Pressure: 0 mmHg at 25°C
Melting Point: 260-262°C
Refractive Index: 1.699
Boiling Point: 672.123°C at 760 mmHg
pKa: pKa1 4.57, pKa2 8.71, pKa3 10.56
Flash Point: 360.287°C
PSA: 107.95000
Density: 1.405 g/cm3
LogP: 1.08550
Product Description:
Top Quality Chinese Manufacturer supply Deferasirox (CAS 201530-41-8).
Pharmacological Effects:
DFS (Deferasirox) has antifungal activity (such as Mucor growing in the iron-rich environment), anti-cell proliferation, anti-malaria, anti-oxidative stress injury, anti-cytotoxicity induced apoptosis and other pharmacological effects.
1. DFS and fungal infection: Iron is a substance that fungi rely on, and plays a very important role in the growth and toxicity of fungi. The antifungal effect of iron chelator may be due to their effect of removal of the iron necessary for fungal growth, so as to achieve the purpose of treatment of fungal infection.
2. DFS and cell proliferation: Iron plays a very important role in the process of cell proliferation. Iron chelators may have anti-proliferative properties, suggesting that iron chelators may be a novel anticancer agent for the treatment of tumors.
Pharmacokinetics:
DFS is a tridentate iron chelator that binds ferric ions in a 2:1 ratio to form complexes that are excreted from the feces, reducing the storage of iron in the body. As DFS persists in plasma, the plasma non-transferring binding iron can be continuously reduced, thus directly eliminating the iron toxicity formed in vivo. The main metabolic pathway of DFS is via glucuronidation for producing metabolites M3 (acylglucuronide) and M6 (2-O-glucuronide).
Side Effects:
- For patients with renal insufficiency, DFS can lead to increased creatinine levels.
- <1% of patients can get hearing impairment and ocular diseases.
- Common side effects: rash, abdominal pain, diarrhea, elevated transaminase and serum creatinine levels.
- Can cause renal damage and gastrointestinal bleeding.
- May lead to serious adverse effects of liver failure.
Precautions:
Patients with allergy to deferasirox are disabled.
Applications:
- Treatment of chronic iron overload
- Iron chelation therapy
- Pharmaceutical API for iron overload conditions
Quality: 99% purity, pharmaceutical-grade product.
Packaging: Available in various package sizes to meet customer requirements.
Storage: Store in a cool, dry place away from light and moisture.
CAS No.: 201530-41-8
Molecular Formula: C21H15N3O4
Molecular Weight: 373.368
Purity: 99%
Vapor Pressure: 0 mmHg at 25°C
Melting Point: 260-262°C
Refractive Index: 1.699
Boiling Point: 672.123°C at 760 mmHg
pKa: pKa1 4.57, pKa2 8.71, pKa3 10.56
Flash Point: 360.287°C
PSA: 107.95000
Density: 1.405 g/cm3
LogP: 1.08550
Product Description:
Top Quality Chinese Manufacturer supply Deferasirox (CAS 201530-41-8).
Pharmacological Effects:
DFS (Deferasirox) has antifungal activity (such as Mucor growing in the iron-rich environment), anti-cell proliferation, anti-malaria, anti-oxidative stress injury, anti-cytotoxicity induced apoptosis and other pharmacological effects.
1. DFS and fungal infection: Iron is a substance that fungi rely on, and plays a very important role in the growth and toxicity of fungi. The antifungal effect of iron chelator may be due to their effect of removal of the iron necessary for fungal growth, so as to achieve the purpose of treatment of fungal infection.
2. DFS and cell proliferation: Iron plays a very important role in the process of cell proliferation. Iron chelators may have anti-proliferative properties, suggesting that iron chelators may be a novel anticancer agent for the treatment of tumors.
Pharmacokinetics:
DFS is a tridentate iron chelator that binds ferric ions in a 2:1 ratio to form complexes that are excreted from the feces, reducing the storage of iron in the body. As DFS persists in plasma, the plasma non-transferring binding iron can be continuously reduced, thus directly eliminating the iron toxicity formed in vivo. The main metabolic pathway of DFS is via glucuronidation for producing metabolites M3 (acylglucuronide) and M6 (2-O-glucuronide).
Side Effects:
- For patients with renal insufficiency, DFS can lead to increased creatinine levels.
- <1% of patients can get hearing impairment and ocular diseases.
- Common side effects: rash, abdominal pain, diarrhea, elevated transaminase and serum creatinine levels.
- Can cause renal damage and gastrointestinal bleeding.
- May lead to serious adverse effects of liver failure.
Precautions:
Patients with allergy to deferasirox are disabled.
Applications:
- Treatment of chronic iron overload
- Iron chelation therapy
- Pharmaceutical API for iron overload conditions
Quality: 99% purity, pharmaceutical-grade product.
Packaging: Available in various package sizes to meet customer requirements.
Storage: Store in a cool, dry place away from light and moisture.
| Short Description | Deferasirox is an oral iron chelator used for the treatment of chronic iron overload. |
|---|---|
| MOQ | 1 Piece |
| Contact supplier for shipping and payment information. |
📦 Shipping costs are estimated and will be confirmed with the supplier.
💳 Payment terms may vary based on order quantity and buyer history.
More Products from Hebei Shengsuan Chemical Industry Co., Ltd
View All Products →Send Inquiry for Deferasirox
Fill out the form below and the supplier will respond to you shortly.